Pegarginase - Bio-Cancer Treatment International

Drug Profile

Pegarginase - Bio-Cancer Treatment International

Alternative Names: BCT-100; PEG-arginase - Bio-Cancer Treatment International; PEG-BCT-100; PEGylated recombinant human arginase - Bio-Cancer Treatment International; Recombinant human arginase 1 - Bio-Cancer Treatment International; Recombinant human arginase I - Bio-Cancer Treatment International; rhArg1 - Bio-Cancer Treatment International; rhArgI - Bio-Cancer Treatment International; rhArgIpeg5000

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator Bio-Cancer Treatment International
  • Class Antineoplastics; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Hepatocellular carcinoma
  • Phase I Solid tumours
  • Suspended Leukaemia; Lymphoma

Most Recent Events

  • 01 Sep 2016 Phase-II trials in Acute myeloid leukaemia (Recurrent, Treatment-resistant, In adults) in Hong Kong (IV) (NCT02899286)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2014 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Arginine auxotrophic) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top